Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-950 in Advanced Solid Tumors and Melanoma
NCT05423262Phase 2Recruiting
- Sponsor
- Toray Industries
- Start
- Jul 2022
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TRK-950 in solid tumor, melanoma, sponsored by Toray Industries. Started Jul 2022; status: recruiting.
02
Drugs
TRK-950
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT05423262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423262.